| 冠心病药物治疗进展 |
| |
| 引用本文： | 常书福.冠心病药物治疗进展[J].金属学报,2022,27(4):405-408. |
| |
| 作者姓名： | 常书福 |
| |
| 作者单位： | 复旦大学附属中山医院心内科，上海市心血管病研究所，上海市放射与治疗（介入治疗）临床医学研究中心，国家放射与治疗临床医学研究中心，上海 200032 |
| |
| 基金项目： | 上海市卫生健康委员会科研课题面上项目（201940152） |
| |
| 摘 要： | 冠心病治疗方法日新月异，不断有新型药物进入临床。抗血小板药物是冠心病治疗的基础，但目前尚无新型药物能撼动阿司匹林和P2Y12受体抑制剂的地位。炎症与冠心病的发生发展息息相关，抗炎治疗初露曙光，仍需进一步深入探索。本文拟就冠心病药物治疗的进展进行总结，为临床实践提供新的视野。
|
| 关 键 词： | 冠心病 抗血小板 炎症 |
Progress of medical treatment of coronary heart disease |
| |
| CHANG Shufu.Progress of medical treatment of coronary heart disease[J].Acta Metallurgica Sinica,2022,27(4):405-408. |
| |
| Authors: | CHANG Shufu |
| |
| Affiliation: | Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Clinical Research Center for Interventional Medicine, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China |
| |
| Abstract: | Coronary heart disease (CHD) treatment methods are changing rapidly, and new drugs are constantly entering the clinic. Antiplatelet drugs are the basis for the treatment of CHD, but there are currently no new drugs that can challenge the status of aspirin and P2Y12 receptor inhibitors. Inflammation is the mechanism of the occurrence and development of CHD, and anti-inflammatory treatment is just beginning, and further exploration is still needed. This paper aims to summarize the progress of drug treatment for CHD and provide a new perspective for clinical practice. |
| |
| Keywords: | coronary heart disease antiplatelet inflammation |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
